These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37748729)

  • 41. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Report on the AAPS Immunogenicity Guidance Forum.
    Myler H; Gorovits B; Phillips K; Devanarayan V; Clements-Egan A; Gunn GR; Kirshner S; DeSilva B; Shah VP
    AAPS J; 2019 Apr; 21(4):55. PubMed ID: 30993501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naïve Subjects.
    Liao K; Derbyshire S; Wang KF; Caucci C; Tang S; Holland C; Loercher A; Gunn GR
    AAPS J; 2018 Mar; 20(3):51. PubMed ID: 29549534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
    Pederson S; Biondi DM; Allan B; Cady R; Schaeffler B; Baker B; Latham J
    Front Immunol; 2021; 12():765822. PubMed ID: 34759933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.
    Chirmule N; Jawa V; Meibohm B
    AAPS J; 2012 Jun; 14(2):296-302. PubMed ID: 22407289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A bridging immunogenicity assay for anti-cabiralizumab antibodies: overcoming the low assay cut point and drug tolerance challenges.
    Yuan L; Gleason CR; Stocker D; Li L; Shen JX; Ji QC
    Bioanalysis; 2021 Mar; 13(5):395-407. PubMed ID: 33661021
    [No Abstract]   [Full Text] [Related]  

  • 50. An electrochemiluminescence assay for quantification of Denileukin Diftitox and its anti-drug antibodies in rat serum.
    Mano Y
    J Pharmacol Toxicol Methods; 2023; 119():107239. PubMed ID: 36526166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.
    Bloem K; Hernández-Breijo B; Martínez-Feito A; Rispens T
    Ther Drug Monit; 2017 Aug; 39(4):327-332. PubMed ID: 28463887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.
    Wang EQ; Bukowski JF; Yunis C; Shear CL; Ridker PM; Schwartz PF; Baltrukonis D
    BioDrugs; 2019 Oct; 33(5):571-579. PubMed ID: 31529318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.
    Harth S; Frisch C
    Methods Mol Biol; 2021; 2261():291-306. PubMed ID: 33420997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance.
    Kavita U; Miller W; Ji QC; Pillutla RC
    AAPS J; 2019 Jul; 21(5):92. PubMed ID: 31332587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics.
    Xue L; Rup B
    AAPS J; 2013 Jul; 15(3):893-6. PubMed ID: 23761225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calibration-free concentration analysis for quantification of anti-drug specific antibodies in polyclonal positive control antibodies and in clinical samples.
    Aniol-Nielsen C; Toft-Hansen H; Dahlbäck M; Nielsen CH; Solberg H
    J Immunol Methods; 2021 Oct; 497():113002. PubMed ID: 33640327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach.
    Tsakok T; Rispens T; Spuls P; Nast A; Smith C; Reich K
    J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):329-337. PubMed ID: 33030275
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Ito S; Ikuno T; Mishima M; Yano M; Hara T; Kuramochi T; Sampei Z; Wakabayashi T; Tabo M; Chiba S; Kubo C
    J Immunotoxicol; 2019 Dec; 16(1):125-132. PubMed ID: 31179789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype.
    Wu Y; Liu X; Chen Y; Woods R; Lee N; Yang H; Chowdhury P; Roskos LK; White WI
    J Pharm Biomed Anal; 2013 Dec; 86():73-81. PubMed ID: 23988731
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.